https://orcid.org/0000-0002-6908-8317
We agree that a point of care method would be useful for clinicians. However, we believe that few individual clinicians would be willing to spend $5000 for the basic machine. A group or laboratory would be more likely to be interested but that would remove it from the category of point of care. There are a number of kits available for PCR detection of clarithromycin resistance that have also been approved for use in clinical laboratories [Citation1,Citation2]. Since Covid became a problem almost every hospital and small laboratory have purchased a PCR machine which is multi-use and this more versatile than a single-use device. We anticipate that now that clinicians recognize the value of susceptibility testing, a number of novel techniques and devices will become available and that we have only now seeing the beginning of the revolution in therapy.
Declaration of interest
DY Graham is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel Helicobacter pylori therapies. He has received research support for culture of H. pylori and is the principal investigator of an international study of the use of anti-mycobacterial therapy for Crohn’s disease. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Author contributions
Both authors were responsible for the concept and writing of the manuscript.
Additional information
Funding
References
- Dore MP, Graham DY. Modern approach to the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther. 2022;55(Suppl 1):S14–S21.
- Graham DY, Moss SF. Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: when, how, why. Am J Gastroenterol. 2022;117(4):524–528.